Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-02-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.01.061PMID 29407963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A mini-review of c-Met as a potential therapeutic target in melanoma.

  2017cited by this paper
• Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

  2017cited by this paper
• Design, synthesis and characterization of novel quinacrine analogs that preferentially kill cancer over non-cancer cells through the down-regulation of Bcl-2 and up-regulation of Bax and Bad.

  2017cited by this paper
• Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present).

  2017cited by this paper
• Design and one-pot synthesis of hybrid thiazolidin-4-one-1,3,5-triazines as potent antibacterial agents against human disease-causing pathogens

  2013cited by this paper
• Synthesis and Biological Evaluation of 4‐Phenoxy‐6,7‐disubstituted Quinolines Possessing Semicarbazone Scaffolds as Selective c‐Met Inhibitors

  2013cited by this paper
• Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.

  2013cited by this paper
• Recent developments and biological activities of thiazolidinone derivatives: a review.

  2012cited by this paper
• Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.

  2011cited by this paper
• XL184 (cabozantinib) for medullary thyroid carcinoma

  2011cited by this paper
• Synthesis, Characterization, Antioxidant and Antitumor Evaluation of Some New Thiazolidine and Thiazolidinone Derivatives

  2011cited by this paper
• Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.

  2010cited by this paper
• Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.

  2009cited by this paper
• N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

  2009cited by this paper
• An efficient synthetic route for quinazolinyl 4-thiazolidinones

  2009cited by this paper
• Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

  2008cited by this paper
• 4-thiazolidinone--a biologically active scaffold.

  2008cited by this paper
• Design, synthesis, and biological evaluation of potent c-Met inhibitors.

  2008cited by this paper
• Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition.

  2008cited by this paper
• Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

  2008cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Synthesis and antimalarial efficacy of aza-fused rhodacyanines in vitro and in the P. berghei mouse model.

  2006cited by this paper
• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  2005cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper

• Thiazolidinedione derivatives: emerging role in cancer therapy

  2025cites this paper
• Discovery of structural diversity guided steroidal thiazolidin-4-one derivatives as potential cytotoxic agents targeting CDK1

  2024cites this paper
• 1,2,3-Triazole Nilotinib Analogues: Synthesis and Cytotoxic Activity

  2024cites this paper
• Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

  2024cites this paper
• MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  2023cites this paper
• Systematic Review on Thiazole Compounds as Nanoparticles: Chemistry, Synthesis, Antimicrobial Activities, Therapeutic Investigation

  2023cites this paper
• Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics

  2023cites this paper
• Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.

  2023cites this paper
• Thiazolidinone‐Heterocycle Frameworks: A Concise Review of Their Pharmacological Significance

  2023cites this paper
• Functionalized Morpholine-thiazole Scaffold: Synthetic Strategies and Applications.

  2023cites this paper
• Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation.

  2022cites this paper
• Preparation of Thiazolidin-4-ones Using NiFe2O4@SiO2 Grafted Propylsulfonic Acid as an Efficient Catalyst

  2022cites this paper
• Access to a Library of 3-(9-Methyl-9H-Carbazol-3-yl)-2-Arylthiazolidin-4-One Derivatives Using NiFe2O4@SiO2 Grafted Alkyl Sulfonic Acid as an Efficient Catalyst

  2022cites this paper
• 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design

  2022cites this paper
• Recent advances in structural modification strategies for lead optimization of tyrosine kinase inhibitors to explore novel anticancer agents.

  2022cites this paper
• Review on recent development of quinoline for anticancer activities

  2022cites this paper
• An alignment-independent three-dimensional quantitative structure-activity relationship study on ron receptor tyrosine kinase inhibitors

  2022cites this paper
• Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.

  2022cites this paper
• Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-).

  2021cites this paper
• Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study.

  2021cites this paper
• Recent contributions of quinolines to antimalarial and anticancer drug discovery research.

  2021cites this paper
• Design, Synthesis and Biological Evaluation of Novel Thiazolidinone Derivatives

  2021cites this paper
• Celastrol: Progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology.

  2020cites this paper
• Discovery of 4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy)-N,N-diethylpiperidine-1-carboxamide as kinase inhibitor for the treatment of colorectal cancer.

  2020cites this paper
• Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents

  2020cites this paper
• Synthesis and antimicrobial agents of thiazolidinone derivatives from benzocyclohepetenone

  2020cites this paper
• SYNTHESIS AND SAR STRATEGY OF THIAZOLIDINEDIONE: A NOVEL APPROACH FOR CANCER TREATMENT

  2020cites this paper
• Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.

  2020cites this paper
• Recent advances in FLT3 inhibitors for acute myeloid leukemia.

  2020cites this paper
• Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.

  2020cites this paper
• Synthesis of some 5‐arylidene‐2‐(4‐acetamidophenylimino)‐thiazolidin‐4‐one derivatives and exploring their breast anticancer activity

  2020cites this paper
• Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.

  2020cites this paper
• Revealing quinquennial anticancer journey of morpholine: A SAR based review.

  2019cites this paper
• Recent Progress in the Development of Small Molecule c-Met Inhibitors.

  2019cites this paper
• Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.

  2019cites this paper
• Research progress of Axl inhibitors.

  2019cites this paper
• Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.

  2019cites this paper
• Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2.

  2019cites this paper
• Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.

  2019cites this paper